Rocket Pharmaceuticals (RCKT) Intangibles (2022 - 2026)

Rocket Pharmaceuticals has disclosed Intangibles across 5 years of filings, most recently posting $25.2 million for Q1 2026.

• Intangibles for Q1 2026 came in at $25.2 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.2 million (changed 0.0% YoY), and the FY2025 annual result was $25.2 million, changed 0.0% from the prior year.
• Intangibles came in at $25.2 million for Q1 2026 at Rocket Pharmaceuticals, roughly flat from $25.2 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $25.7 million in Q4 2022 to a low of $25.2 million in Q3 2023.
• The 5-year median for Intangibles is $25.2 million (2023), against an average of $25.3 million.
• Across the five-year window, Intangibles decreased 2.23% in 2023 and changed 0.0% in 2024, its largest moves.
• Rocket Pharmaceuticals' Intangibles stood at $25.7 million in 2022, then dropped by 2.23% to $25.2 million in 2023, then changed by 0.0% to $25.2 million in 2024, then changed by 0.0% to $25.2 million in 2025, then changed by 0.0% to $25.2 million in 2026.
• The last three Intangibles figures came in at $25.2 million (Q1 2026), $25.2 million (Q4 2025), and $25.2 million (Q3 2025), per Business Quant data.